Oriola-KD Oyj A (OKDAV)

Currency in EUR
1.025
0.000(0.00%)
Closed·
Showing Oriola-KD Oyj A historical data. For real-time data please try another search
Day's Range
1.0201.165
52 wk Range
1.0201.245
Key Statistics
Prev. Close
1.025
Open
1.12
Day's Range
1.02-1.165
52 wk Range
1.02-1.245
Volume
-
Average Volume (3m)
40.78K
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Oriola-KD Oyj A News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Oriola-KD Oyj A Earnings Call Summary for Q1/2026

  • Oriola Q1 2025 net sales rose 10.7% to €49.8M; adjusted EBITDA increased 2.7% to €7.7M with margin improving to 15.4% from 14.8% YoY.
  • Product segment in Finland drove growth, offsetting weakness in advisory services and lower margins from parallel import business operations.
  • Company maintains 2025 guidance, targeting adjusted EBITDA above €35.1M with new strategic goal of minimum 5% annual revenue growth.
  • Major infrastructure investments underway including new Järvenpää distribution center to enhance automation and operational efficiency capabilities.
  • Key risks include geopolitical supply chain uncertainties, inflationary pressures, market saturation in parallel imports, and weak consumer confidence.
Last Updated: 2026-04-29, 04:22 a/m
Read Full Transcript

Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
-0.10 / 0.03
Revenue / Forecast
502.1M / 463.48M
EPS Revisions
Last 90 days

OKDAV Income Statement

Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services. Further, the company provides advisory services. It serves pharmaceutical companies, pharmacies, veterinarians, hospitals, healthcare providers, special stores, retailers, and e-commerce companies. The company was founded in 1907 and is headquartered in Espoo, Finland.

Employees
869
Market
Finland

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.51M4.05%7.70M
Other Institutional Investors
68.25M36.84%69.96M
Public Companies & Retail Investors
109.49M59.10%112.22M
Total
185.25M100.00%189.88M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Seligson & Co Phoebus0.87%1,615,5711,656
Proprius Partners Micro Finland0.81%1,500,0001,538
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.